[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 606
1. Ragazzi E, Pucciarelli S, Seraglia R, Molin L, Agostini M, Lise M, Traldi P, Nitti D: Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. J Mass Spectrom; 2006 Dec;41(12):1546-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS), the plasma protein profile was determined in nine stage IV CRC patients (study group) and nine clean-colon healthy subjects (control group).
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / analysis. Colorectal Neoplasms / blood. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117375.001).
  • [ISSN] 1076-5174
  • [Journal-full-title] Journal of mass spectrometry : JMS
  • [ISO-abbreviation] J Mass Spectrom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


2. Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S: Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer; 2005;5:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT).
  • Initial staging showed 75% and 25% stage II and III tumors, respectively.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):29-35 [9588914.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2114-21 [15956964.001]
  • [Cites] Radiat Res. 2000 Mar;153(3):245-57 [10669545.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2169-77 [11677103.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):885-92 [11895923.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Semin Radiat Oncol. 2003 Jan;13(1):22-30 [12520461.001]
  • [Cites] Semin Radiat Oncol. 2003 Oct;13(4):403-18 [14586830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20 [15093894.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63 [2890160.001]
  • [Cites] Surgery. 1990 Oct;108(4):787-92; discussion 792-3 [2218892.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1352-4 [2276016.001]
  • [Cites] Head Neck. 1991 Mar-Apr;13(2):132-9 [2022478.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1991 Oct;16(5):466-9 [1742894.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jan;174(1):27-32 [1729745.001]
  • [Cites] Hum Pathol. 1992 Sep;23(9):974-9 [1355464.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2454-60 [8095852.001]
  • [Cites] Surg Today. 1993;23(1):21-30 [8461602.001]
  • [Cites] J Pathol. 1993 Mar;169(3):323-8 [8492225.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]
  • [Cites] J Cell Biochem Suppl. 1993;17F:188-91 [8412192.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]
  • [Cites] J Biol Chem. 1996 Apr 19;271(16):9185-8 [8621573.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):375-9 [8665198.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):884-8 [8667988.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):781-5 [8696739.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):643-8 [8891623.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13704-8 [8942998.001]
  • [Cites] Biochim Biophys Acta. 1996 Nov 8;1314(1-2):147-56 [8972728.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):83-6 [9247128.001]
  • [Cites] Pathology. 1997 Aug;29(3):251-4 [9271009.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]
  • [Cites] Radiat Oncol Investig. 1997;5(4):180-6 [9327497.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]
  • [Cites] Radiat Res. 1998 Jun;149(6):579-87 [9611096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91 [9635706.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2787-96 [9652746.001]
  • [Cites] J Pathol. 1998 Jun;185(2):167-74 [9713343.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):188-91 [10096253.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1864-9 [10206306.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2493-506 [10436007.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]
  • (PMID = 15967033.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC1185521
  •  go-up   go-down


3. Phang PT, McGahan CE, McGregor G, MacFarlane JK, Brown CJ, Raval MJ, Cheifetz R, Hay JH: Effects of change in rectal cancer management on outcomes in British Columbia. Can J Surg; 2010 Aug;53(4):225-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a province-wide audit of patients undergoing treatment for rectal cancer in British Columbia in 1996, the 4-year rate of pelvic recurrence for stage 3 rectal cancer was 27%.
  • Relative to the 1996 cohort, there was a decreasing trend in 2-year overall pelvic recurrence rates in the 2003/04 cohort (9.6% v. 6.9%) and a significant decrease in recurrence among patients with stage 3 cancers (18.2% v. 9.2%; p = 0.020).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Colectomy / methods. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD000125 [10796491.001]
  • [Cites] Can J Surg. 2010 Aug;53(4):222-4 [20646394.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] BMJ. 2003 Jul 5;327(7405):33-5 [12842955.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] JAMA. 1999 Sep 1;282(9):867-74 [10478694.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9257-64 [16361623.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1285-92 [17661309.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]
  • [CommentIn] Can J Surg. 2010 Aug;53(4):222-4 [20646394.001]
  • (PMID = 20646395.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2912013
  •  go-up   go-down


Advertisement
4. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


5. Bedaiwy MA, Hussein MR, Biscotti C, Falcone T: Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study. Pathol Oncol Res; 2009 Mar;15(1):81-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage IV endometriosis with extensive pelvic involvement was found in two patients.
  • Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul de sac (four cases); urinary bladder (two cases); sigmoid colon, hemidiaphragms, and uterine vessels (one case each).
  • The endometriotic lesions were associated with uterine leiomyomas (two patients) and adenocarcinoma of the vagina (one patient).
  • One patient had recurred with metastatic adenocarcinoma of the vault.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2002 Mar;32(3):199-206 [11895472.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):387-91 [17270029.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):12-5 [16009147.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1615-23 [16980942.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jul;19(3):276-9 [10907178.001]
  • [Cites] J Reprod Immunol. 2005 Feb;65(1):55-63 [15694967.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):1074-80 [17442376.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:281-92; discussion 293-5, 396-406 [11949955.001]
  • [Cites] Dis Markers. 2007;23(5-6):367-76 [18057520.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):83-6 [16844279.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1003-6 [12873175.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2001 Jun;30(3):169-72 [11866970.001]
  • [Cites] Adv Anat Pathol. 2007 Jul;14(4):241-60 [17592255.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):379-81 [12451571.001]
  • [Cites] Hum Reprod. 2001 Dec;16(12):2668-71 [11726593.001]
  • [Cites] Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):239-42 [14505256.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):85-7 [10192492.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:39-43 [11093060.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):42-51 [12496697.001]
  • [Cites] Fertil Steril. 2002 Oct;78(4):743-9 [12372450.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):83-9 [16258507.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2006 Feb;41(2):111-3 [16640860.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):248-51 [9930148.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:2-10 [11093055.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jun;184(7):1407-11; discussion 1411-3 [11408860.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):376-80 [12801273.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):97-101 [12818453.001]
  • [Cites] Pathol Res Pract. 2006;202(6):433-7 [16513291.001]
  • [Cites] Diagn Cytopathol. 1996 Jun;14(4):331-3 [8725135.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):345-51 [17581423.001]
  • [Cites] Ginekol Pol. 2001 May;72(5):268-72 [11526755.001]
  • [Cites] J Med Genet. 2006 Jan;43(1):84-90 [15930087.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):223-9 [16810057.001]
  • [Cites] Reproduction. 2001 Apr;121(4):581-6 [11277878.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):285-97 [15104291.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1490-501 [17895749.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):401-6 [12352189.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):97-100 [15221651.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2000 Nov;35(11):667-9 [11218895.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1725-7 [15547552.001]
  • (PMID = 18575828.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC: Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer; 2006;6:241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report on the prevalence and potential clinical significance of fascin expression in relation to the progression of colorectal adenocarcinoma and to tumor cell proliferation as measured by Ki67 index.
  • In the clinically-annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal colon (p = 0.009), but was not associated with age, gender, or TNM stage.
  • Patients with stage III/IV adenocarcinomas (n = 62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year overall survival of 11% versus 43% for fascin-negative patients; p = 0.023).
  • Strong and diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter survival in stage III and IV patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Carrier Proteins / biosynthesis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Microfilament Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1947-53 [11106567.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jun;34(6):685-98 [11943599.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3616-23 [12789270.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):14-23 [15037300.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Gene Expr Patterns. 2004 Oct;4(6):637-43 [15465486.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] Science. 1996 May 24;272(5265):1187-90 [8638166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31 [9391129.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] Hum Genomics. 2004 Jan;1(2):134-40 [15601541.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]
  • [ErratumIn] BMC Cancer. 2011;11:488
  • (PMID = 17029629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC1615879
  •  go-up   go-down


7. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.
  • A fiber optic examination of the sigmoid colon detected an ulcerous lesion with a hemorrhage at the anterior rectal wall.
  • A biopsy revealed the lesion to be Group V poorly differentiated adenocarcinoma.
  • After 3 courses of this regimen, a fiber optic examination of the colon conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. den Dulk M, Marijnen CA, Putter H, Rutten HJ, Beets GL, Wiggers T, Nagtegaal ID, van de Velde CJ: Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg; 2007 Jul;246(1):83-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a multivariate analysis, T-stage, N-stage, and tumor location were independent risk factors for CRM.
  • T-stage, N-stage, and CRM were risk factors for LR and age, T-stage, N-stage, CRM, and distance of the inferior tumor margin to the anal verge for OS.
  • CONCLUSION: Age, T-stage, N-stage, CRM, distance of the tumor to the anal verge, and tumor location were independent risk factors for adverse outcome in patients treated with an APR for low rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Complications. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1239-48 [16873440.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20 [12654443.001]
  • [Cites] Br J Surg. 2003 May;90(5):583-92 [12734867.001]
  • [Cites] Colorectal Dis. 2003 Mar;5(2):180-4 [12780910.001]
  • [Cites] Radiother Oncol. 2004 Jul;72(1):15-24 [15236870.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Int J Colorectal Dis. 1988 Jun;3(2):127-31 [3045231.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):410-6 [15932569.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):74-82 [15973104.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5620-7 [16009958.001]
  • [Cites] Eur J Surg Oncol. 2005 Oct;31(8):845-53 [15979269.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9257-64 [16361623.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):105-12 [16302179.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2249-57 [16400512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):323-7 [10661338.001]
  • (PMID = 17592295.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899206
  •  go-up   go-down


9. Seo T, Tatsuguchi A, Shinji S, Yonezawa M, Mitsui K, Tanaka S, Fujimori S, Gudis K, Fukuda Y, Sakamoto C: Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch; 2009 Jun;454(6):667-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in stage I-III patients.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Intramolecular Oxidoreductases / metabolism. Microsomes / enzymology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16355-64 [11847219.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):447-54 [16688727.001]
  • [Cites] J Biochem Mol Biol. 2005 Nov 30;38(6):633-8 [16336776.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):884-9 [11866447.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37937-47 [12835322.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):469-74 [11418684.001]
  • [Cites] Gut. 2006 Jan;55(1):54-61 [16085694.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]
  • [Cites] Br J Pharmacol. 2004 Apr;141(7):1091-7 [15023855.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5 [10377395.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 18;372(1):249-53 [18485889.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):63-75 [15000150.001]
  • [Cites] Hum Pathol. 2007 Dec;38(12 ):1826-35 [17868774.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32775-82 [10922363.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1184-92 [16752205.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 27;306(2):577-81 [12804604.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):225-36 [15531909.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):551-6 [14520691.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3251-9 [18451151.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19396-405 [12626523.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):404-12 [12891542.001]
  • [Cites] J Pathol. 2006 Feb;208(3):356-63 [16353170.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12 ):3971-6 [11751489.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30253-63 [12050152.001]
  • [Cites] Mol Cancer. 2006 Nov 16;5:62 [17107625.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]
  • (PMID = 19412621.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / PTGES protein, human; EC 5.3.99.3 / PTGES2 protein, human; EC 5.3.99.3 / Prostaglandin-E Synthases
  •  go-up   go-down


10. Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M, Sugihara K: Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum; 2006 Mar;49(3):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue samples of primary tumors and metastatic lymph nodes from 150 patients undergoing intentionally curative surgical resections for colorectal adenocarcinoma were immunohistochemically examined for vascular endothelial growth factor-C, cyclooxygenase-2, and CD34 expressions.
  • A significant correlation was found between the expression scores of vascular endothelial growth factor-C and cyclooxygenase-2 (P < 0.0001), and both also were correlated to microvessels density and several clinicopathologic parameters, including primary tumor size, lymph node metastasis, lymphatic invasion, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Lymph Nodes / metabolism. Membrane Proteins / metabolism. Vascular Endothelial Growth Factor C / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474989.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor C; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


11. Wang H, Safar B, Wexner SD, Denoya P, Berho M: The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy. Dis Colon Rectum; 2009 Oct;52(10):1767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy.
  • N1 and N2 stages were regarded as N+ stage.
  • In the nonneoadjuvant group, there was no significant difference in the number of positive lymph nodes (0.5 +/- 0.2 vs. 1.0 +/- 0.3, P = 0.235), N stage (P = 0.265), or patients with N+ stage (7/31 vs. 16/49, P = 0.332) between the two methods, even though the total lymph node harvest was significantly increased by use of the fat clearance method (9.6 +/- 1.3 vs. 27.6 +/- 2.5, P < 0.001).
  • In contrast, the total lymph node retrieval (5.2 +/- 0.6 vs. 20.4 +/- 1.2, P < 0.001), number of positive lymph nodes (0.4 +/- 0.2 vs. 1.2 +/- 0.3, P = 0.007), N stage (P = 0.005), and patients with N+ stage (6/51 vs. 34/106, P = 0.006) were all increased by fat clearance in the neoadjuvant group.
  • Moreover, the number of patients with N+ stage was stratified by T stage level (T0-T4) to eliminate the background bias, and the results were confirmed.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Node Excision / methods. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966611.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Mansilla F, Birkenkamp-Demtroder K, Kruhøffer M, Sørensen FB, Andersen CL, Laiho P, Aaltonen LA, Verspaget HW, Orntoft TF: Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer; 2007 Jun 18;96(12):1896-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microarray analysis on pooled samples has previously identified ZDHHC9 (DHHC9) to be upregulated in colon adenocarcinoma compared to normal colon mucosa.
  • Immunohistochemical analysis was performed on 60 colon adenocarcinomas, previously analysed on microarrays, as well as on tissue microarrays with 40 stage I-IV tumours and 46 tumours from different organ sites.
  • In conclusion, DHHC9 is a gastrointestinal-related protein highly expressed in MSS colon tumours.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 1997 Sep 12;40(19):2971-90 [9301658.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Cell. 1999 Jul 9;98(1):69-80 [10412982.001]
  • [Cites] Neuron. 2004 Dec 16;44(6):987-96 [15603741.001]
  • [Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1746-52 [15705808.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2240-8 [15956967.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31141-8 [16000296.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1309-15 [16152604.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1974-81 [16488996.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):419-28 [16272173.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] World J Gastroenterol. 2006 Aug 7;12(29):4636-9 [16937431.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):38-48 [16774939.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2475-87 [10713171.001]
  • [Cites] Oncol Rep. 2001 Nov-Dec;8(6):1409-13 [11605075.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Sci STKE. 2002 Oct 1;2002(152):pe41 [12359913.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51957-67 [14522980.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Fam Cancer. 2004;3(2):85-91 [15340258.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11541-7 [8626715.001]
  • [Cites] Biochem Pharmacol. 1998 Dec 1;56(11):1411-26 [9827573.001]
  • (PMID = 17519897.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.3.- / Acyltransferases; EC 2.3.1.- / ZDHHC9 protein, human
  • [Other-IDs] NLM/ PMC2359975
  •  go-up   go-down


13. Lin JK, Shen MY, Lin TC, Lan YT, Wang HS, Yang SH, Li AF, Chang SC: Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma. Int J Biol Markers; 2010 Oct-Dec;25(4):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma.
  • RESULTS: Young CRC patients had a higher frequency of advanced disease (58.7%) and mucinous adenocarcinoma (20%) than old CRC patients.
  • Other clinicopathological factors including tumor location, differentiation, lymphovascular invasion, and TNM stage were not associated with the AA genotype of IGF-1.
  • CONCLUSIONS: Older patients had a higher frequency of the AA genotype of IGF-1(-2995 C/A), while younger patients more often had advanced disease and mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Colorectal Neoplasms / genetics. Insulin-Like Growth Factor I / genetics. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21161940.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


14. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N: Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube. Int J Clin Oncol; 2008 Oct;13(5):461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination determined International Federation of Gynecology and Obstetrics (FIGO) stage IIIc MMMT of the right fallopian tube.
  • Of note, multiple tumoral nodules were attached to the sigmoid colon.
  • The tumor attached to the sigmoid colon had shrunk by 60% after chemotherapy.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovariectomy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):114-24 [1330846.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):101-5 [16445618.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):219-22 [15790462.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(1):47-53 [8789433.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jul-Aug;14(4):690-3 [15304169.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):187-92 [8380115.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):278-92 [6086467.001]
  • [Cites] Acta Obstet Gynecol Scand. 1994 Apr;73(4):352-4 [8160547.001]
  • [Cites] Int J Gynecol Cancer. 1999 Jul;9(4):312-316 [11240785.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 1):735-9 [7724104.001]
  • (PMID = 18946759.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer; 2006 Oct 9;95(7):921-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study comparing normal colon to colorectal cancer by proteomics, hnRNP K was identified as being overexpressed in this type of cancer.
  • In normal colon hnRNP K was exclusively nuclear whereas in colorectal cancer the protein localised both in the cytoplasm and the nucleus.
  • There were significant increases in both nuclear (P=0.007) and cytoplasmic (P=0.001) expression of hnRNP K in Dukes C tumours compared with early stage tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Ribonucleoproteins / biosynthesis


16. Horst D, Kriegl L, Engel J, Jung A, Kirchner T: CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer; 2009 Jul;45(11):2034-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
  • Nuclear beta-catenin and CD133 are linked with two hallmarks of colon cancer, wingless-type mouse mammary tumour virus integration site (WNT)-pathway dysregulation and colon cancer stem cells (Co-CSCs), respectively.
  • Herein, we investigated the expression of these markers on serial sections of 162 stage IIA colonic adenocarcinomas.
  • Moreover, we show that their combined evaluation can identify colon cancer cases with vastly reduced survival (hazard ratio (HR) 13.4, 95% confidence interval (CI): 4.7-38.2) and a high risk of tumour progression (HR 6.8, 95%CI: 3.1-15.0).
  • In conclusion, the independence of these markers may on the one hand have implications for their presumed value to identify Co-CSCs; on the other hand it allows their combined analysis to become a powerful tool to identify high risk cases of stage IIA colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Glycoproteins / analysis. Peptides / analysis. beta Catenin / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403300.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides; 0 / beta Catenin
  •  go-up   go-down


17. Vorburger SA, Gloor B, Candinas D: [Tumor surveillance after resection of colorectal cancer]. Ther Umsch; 2008 Jun;65(6):329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because recurrent adenocarcinoma of the colon and rectum (CRC) can still be treated with acceptable 5-year survival rates, tumor surveillance plays an important role.
  • Only in cases where early stage CRC was been completely resected no schematic surveillance must take place.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622956.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


18. Borie F, Tretarre B, Marchigiano E, Daurcs JP, Millat B: Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study. Med Sci Monit; 2005 Jun;11(6):CR266-273
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study.
  • BACKGROUND: In spite of recent advances in our knowledge of tumor biology and therapy, the management and prognosis of patients with colon cancer (CC) revealed by intestinal obstruction or peritonitis (IOP) are not well defined.
  • The primary independent negative prognostic factor in multivariate analysis was the presence of nodal or distant metastases (Dukes' stage D, p=0.0001), followed by lack of chemotherapy (p=0.008), initial treatment in non-specialized hospitals (p=0.01), onset with IOP (p=0.02), low-volume surgeons (p=0.02).
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Intestinal Obstruction / etiology. Peritonitis / etiology

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15917717.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


19. Reddy VB, Aslanian H, Suh N, Longo WE: Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease. World J Gastroenterol; 2008 Aug 7;14(29):4690-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.
  • Examination of the colon was normal.
  • The biopsy of the ileal mass was consistent with an adenocarcinoma arising from the terminal ileum.
  • Findings were consistent with ileal adenocarcinoma in the setting of Crohn's disease.
  • The pathology was stage 1 adenocarcinoma.
  • This is a unique case in that on a screening colonoscopy, a favorable ileal adenocarcinoma was discovered in the setting of asymptomatic, undiagnosed ileal Crohn's disease in a patient whose father had Crohn's disease diagnosed postmortem.
  • [MeSH-major] Adenocarcinoma / diagnosis. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] J Clin Gastroenterol. 1984 Jun;6(3):217-24 [6327804.001]
  • [Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):360-3 [2910443.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1444-51 [1358741.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4 [10574144.001]
  • [Cites] Clin Imaging. 1999 Sep-Oct;23(5):298-301 [10665347.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Australas Radiol. 2003 Dec;47(4):450-2 [14641202.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16 [14716243.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]
  • [Cites] Radiographics. 2004 May-Jun;24(3):689-702 [15143222.001]
  • [Cites] Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4 [15168828.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7 [15181618.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2585-7 [15300912.001]
  • [Cites] Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5 [15326402.001]
  • [Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]
  • [Cites] Gut. 1973 Feb;14(2):120-4 [4696534.001]
  • [Cites] Am J Dig Dis. 1973 Dec;18(12):1095-8 [4761532.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Cancer. 1976 Jun;37(6):2948-59 [949714.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Gut. 1982 Mar;23(3):188-93 [7040175.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Med Clin North Am. 1994 Nov;78(6):1399-412 [7967916.001]
  • [Cites] Gut. 1994 Nov;35(11):1507-8 [7828962.001]
  • [Cites] Am J Gastroenterol. 1996 Mar;91(3):434-40 [8633487.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1315-21 [8918446.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2 [9619392.001]
  • [Cites] Surgery. 1956 Feb;39(2):347-51 [13298987.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5 [12950413.001]
  • (PMID = 18698685.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738795
  •  go-up   go-down


20. Wille-Jørgensen P, Laurberg S, Påhlman L, Carriquiry L, Lundqvist N, Smedh K, Svanfeldt M, Bengtson J: An interim analysis of recruitment to the COLOFOL trial. Colorectal Dis; 2009 Sep;11(7):756-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Prospective registration of all operated patients as well as inclusions (curative resection, stage II or III disease, <or= 75 years, clean colon and exclusions of the individual patients in eight participating departments.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Patient Selection. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708095.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


21. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M: Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg; 2007 Aug;246(2):215-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY BACKGROUND DATA: The incidence of rectal cancer increases with older age, and localized disease can be curatively treated with stage-appropriate radical surgery.
  • METHODS: Patients with localized rectal adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results database (1991-2002).
  • Each half-decade increase in age > or =70 years was associated with a 37% increase in the relative risk (RR) for cancer-related mortality (RR = 1.37; 95% confidence interval [CI], 1.33-1.42); decreased receipt of cancer-directed surgery (odds ratio [OR] = 0.56; 95% CI, 0.36-0.63); more local excision and less radical surgery (OR = 0.76; 95% CI, 0.72-0.81); less radiotherapy (OR = 0.64; 95% CI, 0.61-0.67); and greater likelihood of N0 pathologic stage classification (OR = 1.10; 95% CI, 1.05-1.15) (P < 0.0001 for each factor).
  • [MeSH-major] Adenocarcinoma / epidemiology. Rectal Neoplasms / epidemiology


22. Childs AJ, Burke JJ 2nd, Perry MY, Check WE, Gallup DG: Recurrent colorectal carcinoma detected by routine cervicovaginal papanicolaou smear testing. J Low Genit Tract Dis; 2005 Oct;9(4):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We present a case of recurrent colon cancer detected by routine, annual Papanicolaou screening.
  • CASE: A 59-year-old African American woman who had been treated for T2N0M0 (stage II, Dukes A) colon cancer 2 years before to presentation had a Pap smear showing a high-grade squamous intraepithelial lesion with a normal cervical biopsy result.
  • Because of this discrepancy, a loop electrosurgical excision procedure and endocervical curettage were performed and showed atypical glandular cells suspicious for adenocarcinoma.
  • Subsequent colonoscopy showed recurrent adenocarcinoma of the colon.
  • The patient underwent an en-block total abdominal hysterectomy and anterior-perineal resection showing invasion of recurrent colon cancer into the uterus and cervix.
  • CONCLUSION: In patients with a history of extrauterine adenocarcinoma, abnormal Pap screening may indicate recurrent or metastatic carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Diagnostic Tests, Routine. Neoplasm Recurrence, Local / diagnosis. Papanicolaou Test. Uterine Neoplasms / diagnosis. Vaginal Smears


23. Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A: Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis; 2008 Jan;10(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate survival and prognostic factors in a consecutive series of colon cancer patients from a defined city population in Norway.
  • METHOD: All patients with adenocarcinoma of the colon diagnosed between 1993 and 2000 were registered prospectively.
  • Tumour location in the transverse colon, splenic flexure and descending colon (OR = 1.8), emergency operation (OR = 1.7), TNM stage (OR = 1.8-2.9), blood transfusion of more than two units (OR = 1.8) and age (OR = 4.0-7.1) were independent negative prognostic factors.
  • CONCLUSION: Colon cancer located in the transverse and descending colon is associated with poor prognosis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672872.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol; 2005 Dec 1;23(34):8706-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
  • PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.
  • Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314630.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Morris M, Platell C, Fritschi L, Iacopetta B: Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer; 2007 Mar 12;96(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
  • Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.
  • The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.
  • The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]
  • (PMID = 17299387.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360063
  •  go-up   go-down


26. Qureshi AU, Iqbal M, Gondal KM: Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital. J Coll Physicians Surg Pak; 2009 Jul;19(7):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.
  • The TNM staging were stage I, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
  • The frequency of complications is lower as compared to transthoracic approach and the early stage of presentation can lead to high 5-year survival ratios.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576147.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


27. Mukai M, Tanaka A, Tajima T, Fukasawa M, Yamagiwa T, Okada K, Sato K, Tobita K, Oida Y, Makuuchi H: Two-port hand-assisted laparoscopic surgery for the 2-stage treatment of a complete bowel obstruction by left colon cancer: a case report. Oncol Rep; 2008 Apr;19(4):875-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-port hand-assisted laparoscopic surgery for the 2-stage treatment of a complete bowel obstruction by left colon cancer: a case report.
  • Since a bowel obstruction by left colon cancer was suspected due to a marked dilation of the transverse colon, she was referred to our hospital.
  • On admission, an enema disclosed a complete obstruction at the splenic flexure of the colon.
  • An emergency operation was performed, and a temporary loop colostomy was fashioned on the left side of the transverse colon within the range of resection for 2-stage radical surgery.
  • The histological diagnosis was Type 2 circumferential well-differentiated adenocarcinoma with local peritoneal dissemination.
  • Our experience suggests that 2-stage surgery combined with 2P-HALS is applicable even to a large obstructing left colon cancer.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357370.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


28. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol; 2008 May;19(5):935-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only stage correlated with positive CTCs (20.7% in stage II, 24.1% in stage III and 60.7% in stage IV, P = 0.005).
  • CONCLUSIONS: CTCs detection by CellSearch is a highly reproducible method that correlates with stage but not with other clinical and morphological variables in patients with colorectal cancer.
  • Colon cancer tumor cells are detectable in all stages.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212090.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


29. Yang R, Cheung MC, Zhuge Y, Armstrong C, Koniaris LG, Sola JE: Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases. J Surg Res; 2010 Jun 15;161(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases.
  • OBJECTIVE: To study the outcomes of solid tumors of the colon and rectum in pediatric patients.
  • Tumors were identified in the right colon (45.9%), transverse colon (9.3%), left colon (20.4%), rectum (15.2%), and anal canal (1.1%).
  • The most common histology of these tumors was adenocarcinoma (35.6%), followed by carcinoid (34.1%).
  • Multivariate analysis of the cohort identified tumor stage (HR 8.39, P < 0.001 for distant disease), tumor type (signet ring HR 2.12, P = 0.025, and carcinoid HR = 0.14, P = 0.001), and surgical resection (no surgery HR 2.98, P = 0.010) as independent predictors of worse outcome.
  • CONCLUSION: In the pediatric population, solid tumors of the colon and rectum occur more frequently in the right side of the colon in teenagers.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19285688.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Endreseth BH, Romundstad P, Myrvold HE, Hestvik UE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group: Rectal cancer in the young patient. Dis Colon Rectum; 2006 Jul;49(7):993-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This prospective study from the Norwegian Rectal Cancer Project includes all 2,283 patients younger than aged 70 years with adenocarcinoma of the rectum from November 1993 to December 1999.
  • RESULTS: Patients younger than aged 40 years had significantly higher frequencies of poorly differentiated tumors (27 vs. 12-16 percent; P = 0.014), N2-stage (37 vs. 13-18 percent; P = 0.001), and distant metastases (38 vs. 19-24 percent; P = 0.019) compared with older patients.
  • CONCLUSIONS: Patients younger than aged 40 years had a more advanced stage at the time of diagnosis and poor prognosis compared with older patients.
  • [MeSH-major] Adenocarcinoma / therapy. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741599.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut; 2005 May;54(5):661-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
  • BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression.
  • AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.
  • PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.
  • Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas.
  • Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.
  • CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas.
  • The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1309-13 [10571510.001]
  • [Cites] Cell Death Differ. 2001 Mar;8(3):273-8 [11319610.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5023-7 [10799856.001]
  • [Cites] J Pathol. 2001 May;194(1):15-9 [11329136.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2068-73 [11489989.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):139-48 [12204534.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5973-80 [12794124.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):708-15 [12949717.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4164-74 [14530339.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):930-6 [7226044.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]
  • [Cites] Lab Invest. 1993 Oct;69(4):415-29 [7693996.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):371-7 [8168998.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):709-14 [8782663.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1075-82 [9064324.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1149-54 [9064331.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):160-7 [9207274.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):526-34 [9458101.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1717-23 [9802983.001]
  • [Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1033-8 [10510093.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4941-54 [10779805.001]
  • (PMID = 15831912.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC1774512
  •  go-up   go-down


32. Dahl O: [Adjuvant chemotherapy for colon cancer]. Tidsskr Nor Laegeforen; 2007 Nov 29;127(23):3094-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for colon cancer].
  • BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.
  • The background for adjuvant chemotherapy of colon cancer is presented.
  • RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
  • Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049502.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


33. Chaleoykitti B: Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital. J Med Assoc Thai; 2006 Jan;89(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.
  • OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous adenocarcinoma.
  • MATERIAL AND METHOD: Patients with carcinoma of the colon and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.
  • There was no difference in sex distribution, location of tumors, depth of invasion, lymph node involvement, distant metastasis, TNM stage, lymphatic invasion, vascular invasion, perineural invasion, peritoneal seeding, curability, positive microscopic margin, and adhesion to the surrounding structure.
  • CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous adenocarcinoma of colon and rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583577.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


34. Wang C, Zhou Z, Wang Z, Zheng Y, Zhao G, Yu Y, Cheng Z, Chen D, Liu W: Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum. Langenbecks Arch Surg; 2005 Aug;390(4):312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant difference in occurrence of micrometastasis was observed among tumors of different stage.
  • [MeSH-major] Adenocarcinoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Jun;83(6):781-5 [8696739.001]
  • [Cites] Br J Surg. 1997 May;84(5):652-6 [9171754.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):327-34 [11872058.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):584-8 [9179114.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):388-92 [8625118.001]
  • [Cites] Br J Hosp Med. 1992 Feb 19-Mar 3;47(4):247-8 [1591538.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] Br J Surg. 1997 Nov;84(11):1546-50 [9393276.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):779-85 [12794580.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 16049726.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


35. Tsunoda A, Nakao K, Tsunoda Y, Watanabe M, Matsui N: Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone. Int J Clin Oncol; 2010 Apr;15(2):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with stage II and III carcinoma of the colon.
  • CONCLUSIONS: HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Quality of Life

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Oral Health.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1294-303 [10717609.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2135-44 [9610692.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Dis Colon Rectum. 2006 Nov;49(11):1663-72 [17041749.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):424-30 [17264338.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):810-5 [9797690.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Qual Life Res. 2008 Mar;17(2):317-22 [18095186.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1170-7 [17375049.001]
  • [Cites] Acta Oncol. 2007;46(1):77-82 [17438708.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3466-74 [15277535.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]
  • [Cites] Dis Colon Rectum. 1995 Apr;38(4):361-9 [7720441.001]
  • (PMID = 20191299.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


36. Nabi U, Nagi AH, Riaz S, Sami W: Morphological evaluation of colorectal carcinoma with grading staging and histological types. J Pak Med Assoc; 2010 Dec;60(12):998-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haematoxylin and Eosin stained slides were examined to determine the histological type, grade and stage of CRC.
  • RESULTS: Among the 100 cases, 59 were non mucinous adenocarcinomas, of which 4 were in Dukes' stage A, 51 were in Dukes' stage B and 4 were in Dukes' stage C.
  • In thirty cases of mucinous carcinomas, 18 were in Dukes' stage B and 12 were in Dukes' stage C, of these 2 were of grade I, 20 were of grade II and 8 were of grade III.
  • All the 11 signet ring cell carcinomas were of grade III and in Dukes' stage C.
  • CONCLUSION: Mucin secreting and signet-ring cell adenocarcinomas of colon and rectum are high grade tumours and presented at an advanced stage.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21381550.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


37. Veenhof AA, Bloemena E, Engel AF, van der Peet DL, Meijer OW, Cuesta MA: The relationship of histological tumor regression grade (TRG) and two different time intervals to surgery following radiation therapy for locally advanced rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A T3N0 preoperative tumor stage was found in 21 (75%) patients in the LI group and in 33 (85%) patients in the SI group (p = 0.36).
  • All tumors were histologically proven adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma. Age Factors. Aged. Digestive System Surgical Procedures. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2007 May;22(5):507-13 [17009009.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):563-8 [18070184.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1297-9 [7489148.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):440-5 [15856263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60 [15936556.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):541-8 [12827607.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2025-31 [15657650.001]
  • [Cites] Colorectal Dis. 2002 May;4(3):177-183 [12780612.001]
  • [Cites] Cancer Control. 2003 May-Jun;10(3):205-11 [12794618.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3471-7 [18846402.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • (PMID = 19415307.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Kent AJ, Woolf D, McCue J, Greenfield SM: The use of symptoms to predict colorectal cancer site. Can we reduce the pressure on our endoscopy services? Colorectal Dis; 2010 Feb;12(2):114-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C-reactive protein, albumin and carcinoembryonic antigen are not predictive of cancer site, Duke's stage or influenced by patient age or gender.
  • [MeSH-major] Adenocarcinoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Sigmoidoscopy
  • [MeSH-minor] Anemia / diagnosis. Anemia / etiology. Colon, Ascending / pathology. Constipation / etiology. Diarrhea / etiology. Humans. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Aug;12(8):834-5 [20456465.001]
  • (PMID = 19207710.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y: Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer. World J Gastroenterol; 2009 Aug 21;15(31):3865-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LNgamma2 expression was seen in 57% of patients with biliary tract cancer, and was associated with depth of invasion, histologic type, and advanced stage.
  • The invasive front dominant type was associated with histologic type and advanced stage.
  • Active MMP7 detected by casein zymography was correlated with depth of invasion and advanced stage.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Animals. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):688-92 [15363037.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):782-91 [7943170.001]
  • [Cites] FEBS Lett. 1995 Jul 24;368(3):556-8 [7635220.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Am J Pathol. 1995 Oct;147(4):1123-32 [7573357.001]
  • [Cites] J Biochem. 1996 Dec;120(6):1196-202 [9010770.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1290-6 [9098015.001]
  • [Cites] Science. 1997 Jul 11;277(5323):225-8 [9211848.001]
  • [Cites] J Pathol. 1998 May;185(1):44-52 [9713359.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3313-6 [10416584.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2353-60 [15333466.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7946-52 [16007117.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11228-37 [17145868.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jan;61(1):44-51 [17164111.001]
  • [Cites] J Pathol. 2007 Apr;211(5):516-23 [17318812.001]
  • [Cites] J Pathol. 2007 May;212(1):102-11 [17370299.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):42-53 [17374440.001]
  • [Cites] Curr Probl Surg. 2007 Jul;44(7):396-482 [17693325.001]
  • [Cites] J Pathol. 2007 Oct;213(2):131-9 [17724792.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1129-35 [11238061.001]
  • [Cites] Mol Carcinog. 2001 Feb;30(2):119-29 [11241759.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):896-900 [11309339.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):290-4 [11494227.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91 [14506159.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • (PMID = 19701966.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / RNA, Small Interfering; 0 / kalinin; 170834-93-2 / laminin alpha 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ PMC2731248
  •  go-up   go-down


40. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • A higher proportion of API were diagnosed at regional/distant stage.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


41. Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, Chung IJ, Kim KK, Lee KH, Kweon SS, Joo YE: KITENIN is associated with tumor progression in human gastric cancer. Anticancer Res; 2010 Sep;30(9):3479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: KAI1 COOH-terminal interacting tetraspanin (KITENIN) promotes tumor cell migration, invasion and metastasis in colon, bladder, head and neck cancer.
  • Expression of KITENIN was significantly associated with tumor size, Lauren classification, depth of invasion, lymph node metastasis, tumor stage and poor survival.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / pathology


42. Bellone G, Gramigni C, Vizio B, Mauri FA, Prati A, Solerio D, Dughera L, Ruffini E, Gasparri G, Camandona M: Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. Int J Oncol; 2010 Nov;37(5):1153-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.
  • The simultaneous expression of Endoglin (CD105), transforming growth factor (TGF)-β1 and TGF-β receptor (R) II were quantified in surgical specimens comprising normal human colon, pre-malignant dysplastic tissue, in situ, and invasive colon cancer specimens, at mRNA and protein levels, respectively by real-time PCR and immunohistochemistry.
  • Serum concentrations of soluble Endoglin and TGF-β1 were evaluated. mRNA and CD105+-microvessel density (MVD) increased significantly in dysplastic colon and carcinoma versus normal tissues; values correlated respectively with dysplasia degree and Dukes' stages.
  • TGF-β1 RII was overexpressed in adenoma and carcinoma versus normal samples, but unrelated with dysplasia or Dukes' stage.
  • These findings suggest active angiogenesis occurs in many pre-malignant colon cases and supports more careful evaluation of different chemopreventive agents.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / biosynthesis. Colonic Neoplasms / metabolism. Precancerous Conditions / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Cell Surface / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis. Transforming Growth Factor beta1 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878063.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


43. Kanellos I, Zacharakis E, Kanellos D, Pramateftakis MG, Tsahalis T, Altsitsiadis E, Betsis D: Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol; 2006 Jul 1;94(1):3-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1995 to 2000, 108 patients with adenocarcinoma of the colon or rectum, underwent curative surgery and enrolled in this prospective study.
  • The proportion of patients with portal CEA > or =5 ng/ml was greater in patients with higher stage than in patients with lower stage.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / genetics. Colonic Neoplasms / diagnosis. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788936.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


44. Maggard MA, Yermilov I, Tomlinson JS, Ko CY: Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci; 2009 Mar;54(3):640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are 12 nodes needed to accurately stage T1 and T2 colon cancers?
  • Evaluation of 12 lymph nodes has been mandated to prevent colon cancer understaging.
  • Given that the probability of node metastases is largely associated with T-stage, are <12 nodes substandard for T1 and T2 lesions?
  • In SEER, 61,237 patients undergoing colon cancer resection were identified.
  • For each T-stage, 5-year survival rates were compared for node-negative cancers by using stepwise node cut-point comparisons (4 nodes, <4, etc.).
  • In conclusion, the number of nodes to stage T1 and T2 lesions may be <12.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916 [19003528.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Colorectal Dis. 2008 Mar;10(3):231-8 [18257848.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Surg Oncol. 2002 Oct;81(2):63-9 [12355405.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):958-65 [10888771.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):243-5 [9922000.001]
  • [Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]
  • [Cites] J Surg Oncol. 2008 Apr 1;97(5):383-7 [18163435.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):133-8 [12844262.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7 [16172297.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8 [10211489.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):858-61 [16109663.001]
  • (PMID = 18612817.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Shotar AM: P53 and heat shock protein 70 expressions in colorectal adenocarcinoma. Saudi Med J; 2005 Oct;26(10):1602-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 and heat shock protein 70 expressions in colorectal adenocarcinoma.
  • OBJECTIVE: To examine the localization and over expression of heat shock protein 70 (HSP70) and p53 in patients with colorectal cancer and compared it with control tissue (including normal colon tissue).
  • METHODS: This was a retrospective study of 60 patients with colorectal adenocarcinoma at the Jordan University of Science and Technology (JUST), Irbid, Jordan from 1997 to 2000.
  • Immuno-histochemistry showed that over expression of HSP70 had no statistically significant difference with any of the different prognostic factors assessed, mainly the grade and the stage.
  • Control tissue (normal colon) was negative, p53, cell-cycle-related oncogene product, was strongly over expressed in the nuclei of the cancer cells of the cancer tissue.
  • We found no significant difference in terms of size, patient age, lymph node state, and stage.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. HSP70 Heat-Shock Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16228064.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP70 Heat-Shock Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Nishiyama N, Yamamoto S, Matsuoka N, Fujimoto H, Moriya Y: Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case. Surg Today; 2009;39(8):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case.
  • To our knowledge, there is no case report of the synchronous resection of colon and ureteral carcinomas by laparoscopy, because of the rareness of this combination and the technical difficulties involved.
  • We report a case of simultaneous descending colon and left ureteral carcinomas, both of which were judged to be relatively early stage carcinoma, which we resected successfully laparoscopically.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colonoscopy. Humans. Laparoscopy. Male. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Today. 2007;37(11):1004-8 [17952536.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):364-70 [10955865.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2007 Aug;17 (4):283-6 [17710049.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10 Suppl):S30-6 [17106813.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Jun;14(3):179-81 [15245672.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Urol. 2005 Apr;173(4):1102-7 [15758710.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):92-3 [15668786.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):382-6 [14712100.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):297-300 [16796445.001]
  • [Cites] Urology. 2001 Jan;57(1):133-7 [11164158.001]
  • (PMID = 19639445.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Schiessel R, Novi G, Holzer B, Rosen HR, Renner K, Hölbling N, Feil W, Urban M: Technique and long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum; 2005 Oct;48(10):1858-65; discussion 1865-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers were staged according to the Dukes classification (Stage A in 41 percent, Stage B in 28 percent, and Stage C in 31 percent; median distance from the anal margin, 3 (range, 1-5) cm).
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Carcinoid Tumor / surgery. Colectomy / methods. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086223.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Euanorasetr C, Lertsithichai P: Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy. Gastric Cancer; 2007;10(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy.
  • BACKGROUND: The aim of the present study was to determine the prognostic significance of peritoneal washing cytology (PWC) among Thai patients with gastric adenocarcinoma.
  • METHODS: Medical charts of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005 were reviewed.
  • Factors significantly associated with positive PWC included tumor location, macroscopic findings, histology, depth of tumor invasion, nodal involvement, TNM stage, and angiolymphatic invasion.
  • CONCLUSION: Gastric adenocarcinoma with positive PWC should be considered stage IV disease.
  • PWC should be included in the staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Neoplasms / pathology. Peritoneum / cytology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Gastric Cancer. 2001;4(1):27-33 [11706624.001]
  • [Cites] Surg Gynecol Obstet. 1961 Apr;112:469-74 [13772295.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):71-5 [9808508.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7374-7 [16437646.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):170-6, discussion 176-7 [16455447.001]
  • [Cites] Surg Today. 1999;29(2):111-5 [10030734.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):611-7 [9179118.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] Surg Today. 2005;35(11):919-24 [16249844.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):92-100 [10813130.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):44-7 [2049751.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):1-7 [11957063.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Surg Oncol. 1992 Oct;1(5):341-6 [1341269.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):372-9 [9527060.001]
  • [Cites] Acta Cytol. 1978 Jul-Aug;22(4):225-9 [281825.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):103-7 [10449681.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):520-4 [10027323.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1131-4 [16086213.001]
  • [Cites] Cancer. 1979 Oct;44(4):1476-80 [498022.001]
  • [Cites] Gastric Cancer. 2005;8(4):228-37 [16328597.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):339-41 [15843872.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1419-23 [14532985.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):411-5 [9718170.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):450-4; discussion 455 [7639005.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):437-42 [2160771.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • (PMID = 17334713.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Hashino S, Kobayashi S, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Izumiyama K, Kahata K, Kondo T, Asaka M: Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer. Int J Clin Oncol; 2008 Apr;13(2):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer.
  • A 27-year-old man with advanced colon cancer that was resistant to conventional chemoradiotherapies was treated with reduced-intensity allogeneic peripheral blood stem cell transplantation (PBSCT).
  • The antitumor effect observed in this patient was insufficient for the patient to achieve complete remission, because the disease was at an already widespread and treatment-resistant stage.
  • He finally died of hepatic failure due to extensive liver GVHD 65 months after the diagnosis of the advanced colon cancer and 29 months after the allogeneic PBSCT.
  • Prospective studies are necessary to achieve better clinical results in patients with advanced colon cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Feb;15(2):863-4 [9053517.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(2):255-6; author reply 257-8 [14676774.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Transplantation. 2004 Dec 27;78(12):1740-6 [15614146.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1201-8 [10438707.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(4):253-61 [12621459.001]
  • [Cites] Lancet Oncol. 2001 May;2(5):290-7 [11905784.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4234-6 [12010834.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Blood. 2006 May 1;107(9):3795-803 [16403911.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(12):1161-6 [11803361.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • (PMID = 18463966.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N: Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol; 2008 Sep;15(9):2388-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a difference in survival between right- versus left-sided colon cancers?
  • BACKGROUND: The incidence of right-sided colon cancers has been increasing in recent years.
  • In this study, we have compared the survival of right-and left-sided colon cancers in a longitudinal population-based database.
  • METHODS: A retrospective survival analysis was performed using the Surveillance, Epidemiology, and End Results Program (SEER) database between 1988 and 2003 on subjects who underwent surgical resection for the a primary diagnosis of pathologically confirmed invasive colon adenocarcinoma.
  • Cox proportional hazard regression analysis was used to assess long-term survival outcomes comparing right-sided (cecum to transverse colon, excluding appendix) versus left-sided (splenic flexure to sigmoid, excluding rectum) colon cancers.
  • RESULTS: A total of 77,978 subjects were identified with adenocarcinoma of the colon.
  • By Cox proportional hazard regression analysis, controlling for statistically significant confounders, including age, sex, race, marital status, tumor stage, tumor size, histologic grade, number of lymph nodes examined, and year of diagnosis, right-sided colon cancers were associated with a 5% increased mortality risk compared with left-sided colon cancers (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07).
  • CONCLUSION: On the basis of analysis of information from the SEER database, we found that right-sided colon cancers have a worse prognosis than left-sided colon cancers.
  • The reason for this remains unclear but may be due to biological and/or environmental factors and may have particular bearing, given the rising incidence of right-sided colon cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis. 1997 Jul-Oct;15(4-5):302-11 [9359018.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):46-50 [8508429.001]
  • [Cites] Dis Colon Rectum. 1991 Jan;34(1):56-9 [1991421.001]
  • [Cites] Langenbecks Arch Chir. 1987;371(3):193-200 [2446097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62 [12917207.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]
  • [Cites] Br J Surg. 1998 Feb;85(2):246-8 [9501827.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3831-9 [17606714.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • (PMID = 18622647.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK007713-13; United States / NIDDK NIH HHS / DK / T32 DK007713; United States / NIDDK NIH HHS / DK / T32 DK007713-13; United States / NIDDK NIH HHS / DK / T32DK007713
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS280426; NLM/ PMC3072702
  •  go-up   go-down


51. Chin CC, Yeh CY, Huang WS, Wang JY: Clinical outcome of intersphincteric resection for ultra-low rectal cancer. World J Gastroenterol; 2006 Jan 28;12(4):640-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1995 to 1998, patients with a non-fixed rectal adenocarcinoma (tumor stage T2) preserving the lower margin at 1-3 cm above the dentate line without distant metastasis was enrolled (period I).
  • CONCLUSION: As to ultra-low rectal cancer, intersphincteric resection could provide acceptable local control and cancer-related survival with no permanent stoma in early-staged tumor (tumor stage T2); moreover, preoperative concurrent chemoradiotherapy would make ISR feasible with surgical curative intent in more advanced tumors (tumor stages T3-4).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2000 Jun;43(6):843-50 [10859087.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):465-9 [15729069.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Chir Ital. 2001 Nov-Dec;53(6):765-72 [11824051.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1108-17 [12190675.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):33-7 [12780924.001]
  • [Cites] Tumori. 2003 Mar-Apr;89(2):152-6 [12841662.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):454-7 [12925080.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):459-66 [14978613.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):832-8 [15108027.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2404-9 [15197202.001]
  • [Cites] Int Surg. 1983 Jan-Mar;68(1):7-11 [6853088.001]
  • [Cites] Br J Surg. 1986 Feb;73(2):136-8 [3947904.001]
  • [Cites] Br J Surg. 1986 Feb;73(2):139-41 [3947905.001]
  • [Cites] Br J Surg. 1994 Sep;81(9):1376-8 [7953423.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):986-91 [8797646.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):740-6 [9645742.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1168-75 [10496557.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1506-12 [15455363.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1703-7 [15532809.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):319-22 [15637735.001]
  • [Cites] Ann Chir. 2000 Sep;125(7):618-24 [11051690.001]
  • (PMID = 16489683.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4066102
  •  go-up   go-down


52. Anderin C, Martling A, Hellborg H, Holm T: A population-based study on outcome in relation to the type of resection in low rectal cancer. Dis Colon Rectum; 2010 May;53(5):753-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In multivariate analysis, local pelvic control was significantly associated with neoadjuvant radiotherapy and complete tumor resection, and survival was significantly associated with neoadjuvant radiotherapy, lower tumor stage, female gender, younger age, and complete tumor resection.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Surgery / methods. Outcome and Process Assessment (Health Care). Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20389209.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J: Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis. BMC Health Serv Res; 2009;9:227
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cohorts included patients aged 66+ newly diagnosed with adenocarcinoma of the colon (n = 52,371) or rectum (n = 18,619) between 1992 and 2002 and matched patients from the general Medicare population, followed until death or December 31, 2005.
  • Resource use, including the percentage that used each type of resource, number of hospitalizations, and number of hospital and skilled nursing facility days, was evaluated by stage and subsite.
  • Hospice use rates in the last year of life were calculated by year of service, stage, and subsite for CRC patients who died of CRC.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2000 May;90(5):695-8 [10800415.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204 [18849013.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-104-17 [12187175.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):728-35 [12586813.001]
  • [Cites] JAMA. 2003 May 7;289(17):2238-45 [12734135.001]
  • [Cites] Am J Med. 2003 Jul;115(1):47-53 [12867234.001]
  • [Cites] J Palliat Med. 2003 Oct;6(5):757-68 [14622455.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):315-21 [14722041.001]
  • [Cites] Med Care. 2004 Feb;42(2):116-22 [14734948.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):969-83 [15230937.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Palliat Med. 2005 Mar;19(2):160-2 [15810757.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):323-37 [15862718.001]
  • [Cites] J Pain Symptom Manage. 2007 Mar;33(3):238-46 [17349493.001]
  • [Cites] J Womens Health (Larchmt). 2007 Mar;16(2):214-27 [17388738.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):871-7 [17417782.001]
  • [Cites] Soc Sci Med. 2007 Oct;65(7):1466-78 [17600605.001]
  • [Cites] Health Econ. 2008 Aug;17(8):947-59 [17910108.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • (PMID = 20003294.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2797788
  •  go-up   go-down


54. Kim SS, Ahn CH, Kang MR, Kim YR, Kim HS, Yoo NJ, Lee SH: Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers. Pathology; 2010 Jan;42(1):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, corresponding normal epithelial cells of oesophagus (0%), stomach (8.0%) and colon (5.0%) displayed lower frequencies of CARD6 immunostaining.
  • The CARD6 expression was evident from an early TNM stage (stage I).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Count. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Signal Transduction. Tissue Array Analysis


55. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


56. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ: The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg; 2007 Sep;194(3):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
  • BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.
  • METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.
  • RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.
  • For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
  • For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
  • CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, Wu Q, Wang Y: Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol; 2008 Jul 28;14(28):4562-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The expression of endocan was higher in normal colon and rectum tissue samples than in cancerous tissue samples (mRNA = 92.6%, protein = 36%), and was lower in colorectal cancer tissue samples (mRNA = 70.4%, protein = 36.1%).
  • No correlation was found between staining intensity and clinical parameters such as sex, age, tumor size and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Proteoglycans / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. RNA, Messenger / metabolism. Rectum / metabolism. Rectum / pathology. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):3139-46 [11049995.001]
  • [Cites] Dis Aquat Organ. 2007 May 9;75(3):183-90 [17629112.001]
  • [Cites] Eur J Biochem. 2001 Aug;268(16):4423-9 [11502202.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1713-21 [11742493.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48341-9 [11590178.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Microvasc Res. 2002 Mar;63(2):159-71 [11866539.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):173-86 [12083848.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4765-77 [12101415.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):844-56 [14871811.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):292-302 [15120666.001]
  • [Cites] BMC Cancer. 2003 Nov 27;3:31 [14641932.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jul 15;170(2):167-74 [15087295.001]
  • [Cites] Cancer. 1974 May;33(5):1480-4 [4823490.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20458-64 [8702785.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):397-403 [9487122.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28116-21 [9774430.001]
  • [Cites] Matrix Biol. 2004 Oct;23(6):341-52 [15533755.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1104-10 [15690056.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Biochim Biophys Acta. 2006 Jan;1765(1):25-37 [16168566.001]
  • [Cites] Crit Care Med. 2006 Feb;34(2):532-7 [16424738.001]
  • [Cites] Proteomics. 2006 Feb;6(3):767-74 [16400680.001]
  • [Cites] Microvasc Res. 2006 Nov;72(3):136-45 [16956626.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • (PMID = 18680240.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ESM1 protein, human; 0 / Neoplasm Proteins; 0 / Proteoglycans; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2731287
  •  go-up   go-down


58. Mielko J, Polkowski WP, Skomra DG, Stanisławek AJ, Kurylcio AM, Korobowicz EM: Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region. HPB (Oxford); 2006;8(3):216-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region.
  • BACKGROUND: p27(kip1) is a tumour suppressor gene, functioning as a cyclin-dependent kinase inhibitor, and an independent prognostic factor in breast, colon, and prostate adenocarcinomas.
  • Conflicting data are reported for adenocarcinoma of the pancreas.
  • The aim of this study was to establish the prognostic value of p27(kip1) expression in adenocarcinoma of the pancreatic head region.
  • There were no significant correlations between p27(kip1) index and stage or lymph node involvement.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Pancreas. 2004 Apr;28(3):231-4 [15084962.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):955-61 [15525823.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Mol Cell. 1998 Mar;1(4):553-63 [9660939.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2181-6 [8572621.001]
  • [Cites] Pancreas. 1999 Jan;18(1):104-10 [9888666.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):459-66 [8630952.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2659-68 [8669843.001]
  • [Cites] Nat Med. 1996 Nov;2(11):1204-10 [8898746.001]
  • [Cites] Int J Pancreatol. 1996 Dec;20(3):155-61 [9013275.001]
  • [Cites] J Immunother. 1997 Jan;20(1):70-8 [9101416.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1463-8 [9356873.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5441-5 [9407946.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1250-60 [10189129.001]
  • [Cites] Eur J Surg. 1999 Apr;165(4):292-306 [10365829.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Am Surg. 1999 Dec;65(12):1143-9 [10597062.001]
  • [Cites] Oncology. 2000;58(1):45-51 [10644940.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] J Pathol. 2000 Jun;191(2):154-61 [10861575.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):36-40 [10861607.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2726-34 [10914717.001]
  • [Cites] Pancreas. 2000 Oct;21(3):226-30 [11039465.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):709-15 [11562745.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1808-15 [12060621.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1591-600 [12655514.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):385-90 [12733121.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):142-6 [14607668.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):685-90 [14608893.001]
  • [Cites] Oncology. 2003;65(4):371-7 [14707458.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):277-84 [14719054.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):10-4 [15053037.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):675-81 [15363035.001]
  • (PMID = 18333280.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131676
  •  go-up   go-down


59. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol; 2009 Jul;22(7):922-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SIRT1 was not significantly related with age, sex, tumor location, stage, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, beta-catenin, COX-2, or patient prognosis.
  • In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2767-73 [18366060.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):534-41 [18516290.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):177-86 [18471961.001]
  • [Cites] PLoS One. 2008;3(11):e3698 [19002263.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1533-41 [18849918.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5713-20 [18955444.001]
  • [Cites] Mod Pathol. 2008 Nov;21(11):1403-12 [18587323.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):151-60 [19011600.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2105-8 [15604409.001]
  • [Cites] Cell. 2005 Feb 25;120(4):473-82 [15734680.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1121-4 [16143149.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] PLoS Genet. 2006 Mar;2(3):e40 [16596166.001]
  • [Cites] Nat Genet. 2006 May;38(5):566-9 [16642021.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):209-17 [16645207.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e77 [16362078.001]
  • [Cites] Gut. 2006 Jul;55(7):1000-6 [16407376.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):582-8 [17065427.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):15-22 [17086168.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):375-83 [17277760.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Genes Dev. 2000 May 1;14(9):1021-6 [10809662.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):255-62 [11089983.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2383-96 [12006491.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):378-83 [12379856.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):370-7 [12410229.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6011-4 [12414620.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Nat Rev Genet. 2007 Apr;8(4):286-98 [17339880.001]
  • [Cites] Biochem J. 2007 May 15;404(1):1-13 [17447894.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):49-55 [17464246.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):305-14 [17591929.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):569-77 [17710160.001]
  • [Cites] Gut. 2007 Nov;56(11):1498-500 [17938428.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1183-90 [17873897.001]
  • [Cites] Nat Rev Genet. 2007 Nov;8(11):829-33 [17909537.001]
  • [Cites] Nat Rev Genet. 2007 Nov;8(11):835-44 [17909538.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):434-9 [18048385.001]
  • [Cites] Epigenetics. 2008 Jan-Feb;3(1):28-37 [18326939.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S23-30 [18437170.001]
  • (PMID = 19430421.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA122826-02; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / CA122826-02; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / CA055075-15; United States / NCI NIH HHS / CA / P50 CA127003-02; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA055075-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  • [Other-IDs] NLM/ NIHMS100427; NLM/ PMC2704253
  •  go-up   go-down


60. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Wide local excision is the mainstay of treatment for early stage tumors as it preserves continence and obtains adequate local control.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


61. Messalli EM, Scaffa C, Mainini G, Rotondi M, Pecori E, Cobellis L: Third stage ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment. Eur J Gynaecol Oncol; 2006;27(3):291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Third stage ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment.
  • Excellent cytoreduction with peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy (Figure 2), bilateral pelvic lymphadenectomy, total omentectomy, removal of nodules from the mesentery, the colon and three nodules in the abdominal wall thickness was executed.
  • The histological report was G3, angioinvasive bilateral ovarian endometrioid adenocarcinoma.
  • It is concluded that the complexity of similar cases always requires a multidisciplinary approach as in our case, involving an oncologist, hematologist, surgeon, gynaecologist, radiologist, anaesthesiologist, and nursing staff in the management of third stage ovarian cancer patients to obtain the best treatment thus guaranteeing a higher survival rate and better quality of life.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800262.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


62. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L: Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer; 2009 Oct;8(4):215-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome.
  • BACKGROUND: Patients infected with Human immunodeficiency virus (HIV) living longer with antiretroviral therapy (ART) are more likely to develop non-AIDS-defining cancers such as adenocarcinoma of the colon.
  • There have been limited case reports regarding HIV-associated colon adenocarcinoma.
  • The aim of this study was to characterize the clinicopathologic findings and outcome in a series of HIV-infected patients diagnosed and treated for colon adenocarcinoma.
  • PATIENTS AND METHODS: A retrospective study involving HIV-related colon adenocarcinoma was performed.
  • Most carcinomas (57%) involved the right colon, were largely TNM stage 4 cancers (47%), and, when present, metastases were mainly to the liver.
  • Immunosuppression (AIDS diagnosis and/or CD4+ < 500 cells/mm3) did not appear to correlate with tumor grade, stage, or an adverse outcome.
  • CONCLUSION: These data show that HIV-infected patients with adenocarcinoma of the colon tend to be young men with a high incidence of right-sided involvement.
  • Additional research is needed to determine if screening HIV-infected individuals for colon cancer should include younger patients and involve the entire colon.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. HIV Infections / complications

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822512.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Johnston MH: Technology insight: ablative techniques for Barrett's esophagus--current and emerging trends. Nat Clin Pract Gastroenterol Hepatol; 2005 Jul;2(7):323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These techniques have been developed primarily to treat the precursors of esophageal adenocarcinoma: dysplasia in Barrett's esophagus and early esophageal cancer.
  • Although high-grade dysplasia and early stage cancer can be treated with esophagectomy, the inherent morbidity and mortality of esophageal adenocarcinoma and the morbidities, difficulties, costs and limitations of the current technology mean that there has been a significant increase in interest and research regarding alternative treatments such as ablative techniques.
  • At this stage it is not clear which of the numerous endoscopic ablative techniques available-photodynamic therapy, laser therapy, multipolar electrocoagulation, argon plasma coagulation, endoscopic mucosal resection, radiofrequency ablation or cryotherapy-will emerge as superior.
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / therapy. Esophageal Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265286.001).
  • [ISSN] 1743-4378
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


64. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):592-8 [18936572.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2283-92 [12436433.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5910-7 [19018087.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):35-41 [18987915.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Oncologist. 1999;4(3):197-208 [10394588.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1829-35 [18662955.001]
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Iannello S, Milazzo P, Bordonaro F, Belfiore F: Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review. MedGenMed; 2006;8(4):60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A fortuitous observation was made by the first author of this study who, at age 54, developed an erythematous and painful postsurgical abdominal keloid scar after undergoing left colectomy for colon adenocarcinoma.
  • During the posttraumatic or postoperative stage, it is useful to achieve the best possible aesthetic results and to decrease the risk of a disfiguring keloid scar, thereby avoiding revision surgery; to this purpose, an early treatment with a low dose of enalapril is a possible solution, even if further confirmatory observations are needed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Sep;127(9):1145 [11556871.001]
  • [Cites] Can J Cardiol. 2000 May;16(5):617-25 [10833541.001]
  • [Cites] J Dermatol Sci. 2002 May;29(1):26-34 [12007718.001]
  • [Cites] Plast Reconstr Surg. 2002 Aug;110(2):560-71 [12142678.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):535-43; discussion 544-6 [12560674.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):547-53; discussion 554-5 [12560675.001]
  • [Cites] Plast Reconstr Surg. 2003 May;111(6):1853-9 [12711944.001]
  • [Cites] J Craniofac Surg. 2003 Sep;14(5):654-7 [14501323.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L156-64 [12754187.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):123-36 [15032619.001]
  • [Cites] Wound Repair Regen. 2004 Mar-Apr;12(2):169-74 [15086768.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):850-3 [15153883.001]
  • [Cites] BMJ. 2004 Jun 5;328(7452):1329-30 [15178589.001]
  • [Cites] Br J Radiol. 1990 May;63(749):349-54 [2198982.001]
  • [Cites] J Am Coll Cardiol. 1992 Mar 1;19(3):713-21 [1538033.001]
  • [Cites] Aust N Z J Med. 1992 Oct;22(5 Suppl):601-6 [1449447.001]
  • [Cites] J Dermatol Surg Oncol. 1993 Aug;19(8):738-46 [8349914.001]
  • [Cites] Cardiovasc Res. 2000 May;46(2):250-6 [10773228.001]
  • [Cites] J Mol Cell Cardiol. 1997 Aug;29(8):2001-12 [9281434.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):418-32 [9339286.001]
  • [Cites] J Am Coll Cardiol. 1998 Aug;32(2):552-3 [9708494.001]
  • [Cites] Plast Reconstr Surg. 1998 Nov;102(6):1954-61 [9810991.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):L1013-7 [9815121.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1273-8 [9824106.001]
  • [Cites] Br J Radiol. 1999 Dec;72(864):1222-4 [10703484.001]
  • [Cites] J Lab Clin Med. 1993 Oct;122(4):395-403 [8228553.001]
  • [Cites] Int J Radiat Biol. 2000 Apr;76(4):523-32 [10815633.001]
  • [Cites] Proc Soc Exp Biol Med. 1994 Jan;205(1):80-4 [8115354.001]
  • [Cites] Rev Prat. 1994 Sep 1;44(13):1763-8 [7939260.001]
  • [Cites] Int J Oral Maxillofac Surg. 1994 Aug;23(4):232-6 [7798696.001]
  • [Cites] Circulation. 1995 Feb 1;91(3):802-12 [7828309.001]
  • [Cites] Cardiovasc Drugs Ther. 1997 Apr;11(2):177-85 [9140694.001]
  • [Cites] Surg Clin North Am. 1997 Jun;77(3):701-30 [9194888.001]
  • [Cites] J Mol Cell Cardiol. 1997 May;29(5):1375-86 [9201623.001]
  • [Cites] Eur J Dermatol. 1998 Dec;8(8):591-5 [9889433.001]
  • [Cites] Ann Plast Surg. 1999 Aug;43(2):179-84 [10454326.001]
  • [Cites] Plast Reconstr Surg. 1999 Sep;104(3):694-8 [10456520.001]
  • [Cites] Plast Reconstr Surg. 1999 Oct;104(5):1435-58 [10513931.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H108-13 [15722410.001]
  • [Cites] Plast Reconstr Surg. 2005 Aug;116(2):675 [16079716.001]
  • [Cites] J Histochem Cytochem. 2005 Oct;53(10):1245-56 [15956033.001]
  • [Cites] Plast Reconstr Surg. 2005 Oct;116(5):1387-90; discussion 1391-2 [16217483.001]
  • [Cites] Plast Reconstr Surg. 2005 Dec;116(7):150e-157e [16327593.001]
  • [Cites] Plast Reconstr Surg. 2006 Jan;117(1):247-52 [16404275.001]
  • [Cites] Plast Reconstr Surg. 2006 Jan;117(1):286-300 [16404281.001]
  • [Cites] Plast Reconstr Surg. 2006 Apr 15;117(5):1645-6 [16641743.001]
  • [Cites] Plast Reconstr Surg. 2001 Oct;108(5):1218-24 [11604622.001]
  • (PMID = 17415337.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 69PN84IO1A / Enalapril
  • [Number-of-references] 48
  • [Other-IDs] NLM/ PMC1868346
  •  go-up   go-down


66. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol; 2008 Dec;16(6):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in adenocarcinoma of the breast, colon, stomach, and ovary, generally reflecting a more aggressive phenotype.
  • We analyzed alphavbeta6 expression in the tissue from primary endometrial carcinomas (endometrioid type) using a mouse monoclonal antibody against human alphavbeta6, and correlated the findings with grade, stage, and nodal involvement.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698261.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
  •  go-up   go-down


67. Paduch R, Kandefer-Szerszeń M, Piersiak T: The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs. Oncol Res; 2010;18(9):419-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
  • We analyzed the levels of reactive oxygen species (ROS), nitric oxide (NO), and cachexia-mediated cytokines (IL-1beta, IL-6, TNF-alpha) in cocultures of human colon carcinoma spheroids prepared with cells derived from tumors of different grades with human normal colon epithelial and myofibroblast cells and normal endothelial cells.
  • The results indicated that adhesion of colon carcinoma spheroids to colon epithelium and myofibroblast monolayers induced O2- anion production but decreased NO levels compared to the sum of the radicals released by monocultures of the two types of cells.
  • Coculture of colon carcinoma spheroids with endothelium was an exception to this rule, as only HT29 cells decreased NO production.
  • However, the levels of released ROS and NO were dependent on the stage of colon carcinoma that the cells were derived from.
  • In conclusion, cytotoxic drugs may, dependent on the stage of tumor growth or the type of chemotherapy regimen administered, significantly influence the proinflammatory cytokine network and local ROS and NO levels.
  • On the other hand, high level of NO seems to facilitate tumor cell interactions with the endothelium and metastasis as NO production was the highest in a monoculture of HUVEC and remained at high levels in cocultures of colon cancer cells with HUVEC.
  • Among the proinflammatory cytokines, only IL-6 seems to significantly influence colon carcinoma development and metastasis.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Camptothecin / administration & dosage. Coculture Techniques. Colon / drug effects. Colon / metabolism. Colon / pathology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Enzyme-Linked Immunosorbent Assay. Fibroblasts / drug effects. Fibroblasts / metabolism. Fibroblasts / pathology. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Metastasis

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524400.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Reactive Oxygen Species; 31C4KY9ESH / Nitric Oxide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


68. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • There were 6 patients (4%) Dukes stage I TNM, 61 stage II (40, 7%), 51 stage III TNM (34%) and 32 patients stage IV TNM (34%).
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


69. Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH: Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer. Int J Colorectal Dis; 2009 Nov;24(11):1297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
  • OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.
  • MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.
  • In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.
  • Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
  • CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 19479270.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Baccari P, Bisagni P, Crippa S, Sampietro R, Staudacher C: Operative and long-term results after one-stage surgery for obstructing colonic cancer. Hepatogastroenterology; 2006 Sep-Oct;53(71):698-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative and long-term results after one-stage surgery for obstructing colonic cancer.
  • BACKGROUND/AIMS: To analyze retrospectively the operative results and five-year survival after single-stage resection and primary anastomosis for right- or left-sided colonic malignant obstruction.
  • METHODOLOGY: From 1994 to 2002, 83 patients with acute obstruction due to primary cancer underwent a one-stage procedure, 36 (43.3%) for cancer of the right and 47 (56.7%) of the left colon.
  • CONCLUSIONS: One-stage resection and primary anastomosis can be applied to the majority of patients with malignant colonic obstruction and it allows achieving excellent operative results.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colectomy. Colonic Neoplasms / drug therapy. Intestinal Obstruction / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086871.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


71. Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF: POSSUM predicts decreased overall survival in curative resection for colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):825-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk factors for overall survival were advanced stage of disease, poor tumor differentiation, mucinous adenocarcinoma, older than age 70 years, and poor condition of the patient at time of operation.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550320.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Tsuneoka M, Teye K, Arima N, Soejima M, Otera H, Ohashi K, Koga Y, Fujita H, Shirouzu K, Kimura H, Koda Y: A novel Myc-target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma. J Biol Chem; 2005 May 20;280(20):19977-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas specific inhibition of mimitin expression did not affect cell proliferation in human cervical carcinoma, colon adenocarcinoma, and hepatocarcinoma cell lines, it did suppress cell proliferation in human glioblastoma, esophageal squamous cell carcinoma (ESCC), and embryonic lung fibroblastic cells, with the greatest suppression efficiency in ESCC cells.
  • The expression level of Mimitin was found to be correlated with that of c-Myc and cell proliferation, but not with the histopathological grade, stage of cancer, or age of patients.


73. Ogata H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Ito Y, Fujita M, Tsubaki M, Kato H, Fujimori T, Fukui H: GROα promotes invasion of colorectal cancer cells. Oncol Rep; 2010 Dec;24(6):1479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the expression of GROα and its pathophysiological significance in human CRCs and investigated whether GROα promotes the invasive potential of colon cancer cells.
  • The mRNA expression of GROα and its receptor CXCR2 was examined in ten colon cancer cell lines using RT-PCR.
  • GROα expression was significantly associated with tumor size, tumor stage, depth of invasion, LN metastasis and patient survival (P=0.021, P<0.0001, P=0.0033, P<0.0001, P=0.039, respectively).
  • Expression of CXCR2 mRNA was detectable in all ten colon cancer cell lines examined, whereas expression of GROα mRNA was detectable in six.
  • [MeSH-major] Adenocarcinoma / pathology. Chemokine CXCL1 / physiology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042742.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1
  •  go-up   go-down


74. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • On multivariate analysis, a significant difference was observed in patients with stage II cancer that was not observed in other stages.
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with stage II colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102402.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


75. Preis M, Korc M: Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther; 2010 May 15;9(10):754-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States.
  • The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread.
  • The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20234186.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-R37-75059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


76. Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB: Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther; 2009 Sep;8(17):1671-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mirk/Dyrk1B is a serine/threonine kinase that has been found to be upregulated in solid tumors and mediates cell survival in colon cancer, pancreatic ductal adenocarcinoma and rhabdomyosarcomas.
  • Using automated quantitative determination of the Mirk protein in tumor specimens of patients with early-stage lung cancer, overexpression of Mirk was found in nearly 90% of tumor specimens in both the cytoplasm and nucleus.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3631-7 [10910078.001]
  • [Cites] J Hematol Oncol. 2009;2:2 [19159467.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1389-99 [11163212.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4150-65 [12833138.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41347-54 [12902328.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22498-504 [15010468.001]
  • [Cites] Clin Lung Cancer. 2004 Sep;6(2):113-22 [15476597.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25893-902 [9748265.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jan 19;254(2):474-9 [9918863.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1999;62:1-17 [9932450.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8288-94 [16322287.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4149-58 [16618736.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5143-50 [16707437.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5542-8 [16740687.001]
  • [Cites] Cell Biochem Biophys. 2006;45(3):303-15 [16845176.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):800-8 [17314339.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40 [17671156.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):274-9 [17583556.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2652-63 [17913856.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):141-51 [11150545.001]
  • (PMID = 19633423.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121182; United States / NCI NIH HHS / CA / 1R01 CA121182-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / bcl-2 Homologous Antagonist-Killer Protein; EC 2.7.1.- / Dyrk kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS521373; NLM/ PMC3839311
  •  go-up   go-down


77. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I, Kiss I: GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res; 2008 May-Jun;28(3B):1917-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated.
  • A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival.
  • CONCLUSION: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Glutathione Transferase / genetics. Tumor Suppressor Protein p53 / genetics


78. Lan YT, Lin JK, Li AF, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC: Metachronous colorectal cancer: necessity of post-operative colonoscopic surveillance. Int J Colorectal Dis; 2005 Mar;20(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 3,846 cases of adenocarcinoma of the colon and rectum, which received curative resection during this period, were found.
  • The age, gender of the patients, the location, pathological characteristics of the metachronous tumors, occurrence of associated adenomas, the number of lesions, and the tumor stage were analyzed and compared with the control group.
  • [MeSH-major] Adenocarcinoma / surgery. Colonoscopy. Colorectal Neoplasms / surgery. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1982 Sep;25(6):569-74 [7117062.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):388-93 [8458267.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1870-4 [6478423.001]
  • [Cites] Ann Intern Med. 2002 Feb 19;136(4):261-9 [11848723.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):603-8 [9152192.001]
  • [Cites] Br J Surg. 1990 May;77(5):502-5 [2354331.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):897-901 [9692559.001]
  • [Cites] Cancer Detect Prev. 1993;17(3):417-24 [8402729.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1093-9 [10950007.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1312 [10561194.001]
  • (PMID = 15349739.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Baron S, Vangheluwe P, Sepúlveda MR, Wuytack F, Raeymaekers L, Vanoevelen J: The secretory pathway Ca(2+)-ATPase 1 is associated with cholesterol-rich microdomains of human colon adenocarcinoma cells. Biochim Biophys Acta; 2010 Aug;1798(8):1512-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The secretory pathway Ca(2+)-ATPase 1 is associated with cholesterol-rich microdomains of human colon adenocarcinoma cells.
  • Within this pathway, the membranes of the Golgi complex represent a transition stage between the cholesterol-poor membranes of the endoplasmic reticulum (ER) and the cholesterol-rich plasma membrane.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcium-Transporting ATPases / chemistry. Calcium-Transporting ATPases / metabolism. Cholesterol / chemistry. Cholesterol / metabolism. Colonic Neoplasms / metabolism. Membrane Microdomains / chemistry. Membrane Microdomains / metabolism

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20363212.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Recombinant Fusion Proteins; 97C5T2UQ7J / Cholesterol; EC 3.6.3.8 / ATP2A2 protein, human; EC 3.6.3.8 / ATP2C1 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases
  •  go-up   go-down


80. Kiran RP, Tripodi G, Frederick W, Dudrick SJ: Adenosquamous carcinoma of the colon: a rare tumor. Am Surg; 2006 Aug;72(8):754-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the colon: a rare tumor.
  • Adenosquamous carcinoma of the colon is rare.
  • Survival for more advanced stages of disease is lower than for patients with adenocarcinoma at a corresponding stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913323.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Miyazaki K, Satoh H, Sekizawa K: Metastasis to appendix from lung adenocarcinoma. Int J Gastrointest Cancer; 2005;36(1):59-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to appendix from lung adenocarcinoma.
  • We previously read with interest the case report by Filik et al. (International Journal of Gastrointestinal Cancer, 2003;34:55-58) on appendicular metastases from pancreatic adenocarcinoma.
  • His past medical history included a pneumonectomy of the left lung for locally advanced lung adenocarcinoma 9 mo previously.
  • TNM stage of the original lung cancer was T2N2M0.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Gastrointest Cancer. 2003;34(1):55-8 [15235136.001]
  • [Cites] Pathol Int. 1996 Mar;46(3):216-20 [10846573.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(1):55-8 [15235136.001]
  • [Cites] Dis Colon Rectum. 1970 Jul-Aug;13(4):336-40 [5459822.001]
  • (PMID = 16227637.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Ahn CH, Jeong EG, Lee JW, Kim MS, Kim SH, Kim SS, Yoo NJ, Lee SH: Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS; 2007 Dec;115(12):1344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, normal mucosal cells of both stomach and colon showed no or very weak expression of beclin-1.
  • There was no significant association of beclin-1 expression with clinocopathologic characteristics, including invasion, metastasis and stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / biosynthesis. Colorectal Neoplasms / metabolism. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184403.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


83. Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2542-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy].
  • An 80-year-old female patient was undergone sigmoidectomy with D2 lymph node dissection for type 2 sigmoid colon cancer in February 2007.
  • A post operative pathological finding of cancer was SS, N0, P0, H0, M0 (Stage II), curative A.
  • In May 2008, total hysterectomy, bilateral oophorectomy, and partial omentectomy were performed and its pathological finding was metastatic ovarian tumor originating from colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224633.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


84. You YN, Baxter NN, Stewart A, Nelson H: Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg; 2007 May;245(5):726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.
  • SUMMARY BACKGROUND DATA: Despite the lack of level I/level II evidence supporting its oncologic adequacy, LE is performed for stage I rectal cancer.
  • METHODS: Surgical therapy for 35,179 patients with stage I rectal cancer diagnosed in 1989 to 2003 was examined over time, utilizing the National Cancer Database.


86. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer; 2008 May 15;122(10):2255-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
  • We evaluated the clinicopathological features and the prognosis of patients with activated-network colon cancers in a population-based study.
  • A total of 586 colon adenocarcinomas were evaluated using sequencing for mutations of KRAS and PI3KCA, and allelic discrimination for mutation of BRAF.
  • These results remained significant in a multivariate analysis adjusted for sex, age, location, stage and microsatellite instability (HR = 1.48; CI CI(95%) = [1.07-2.04]).
  • Our study is the first report to underline the potential role of RAS-MAPK, PI (3)K network mutations on survival in colon cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Mitogen-Activated Protein Kinases / genetics. Mutation / genetics. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18224685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


87. García-Oria Serrano MJ, Armengol Carrasco M, Ortiz R, Codina Cazador A: [The impact of obesity on the histopathological characteristics of colorectal tumours. An observational study]. Cir Esp; 2010 Jan;87(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Impacto de la obesidad en las características anatomopatológicas de los tumores colorrectales. Estudio observacional.
  • Patients subjected to curative elective colorectal cancer surgery at Hospital Josep Trueta de Girona (Spain), from 1990 to 2001.
  • RESULTS: A total of 369 patients with colorectal cancer were included into the study, 213 (57.7%) with colon cancer, and 156 (42.3%) with rectal cancer.
  • For colon cancer patients, when the BMI was higher than 25 kg/m(2), the tumour grade was worst (P=0.011), and when BMI was above 30 kg/m(2) there were more lymph node metastasis.
  • For rectal tumours, the higher the BMI, the more lymph node metastasis (P=0.041), and higher tumour stage (P=0.023).
  • In the case of colon cancer they also have worst tumour grades, and in the case of rectal cancer, a more advanced tumour stage.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 AEC. Published by Elsevier Espana. All rights reserved.
  • (PMID = 19914612.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


88. Zwahlen D, Jezioranski J, Chan P, Haider MA, Cho YB, Yeung I, Levin W, Manchul L, Fyles A, Milosevic M: Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1157-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: A total of 20 patients with International Federation of Gynecology and Obstetrics Stage IB-IV cervical cancer had an MRI-compatible intrauterine BT applicator inserted after external beam radiotherapy.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Colon, Sigmoid / anatomy & histology. Feasibility Studies. Female. Humans. Middle Aged. Radiation Injuries / prevention & control. Radiotherapy Dosage. Rectum / anatomy & histology. Tumor Burden. Urinary Bladder / anatomy & histology


89. Korkolis DP, Plataniotis GD, Gondikakis E, Xinopoulos D, Koulaxouzidis GV, Katsilieris J, Vassilopoulos PP: Short-term preoperative radiotherapy is a safe approach for treatment of locally advanced rectal cancer. Int J Colorectal Dis; 2006 Jan;21(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore evaluated early postoperative complications in patients treated with neoadjuvant radiotherapy for locally advanced rectal adenocarcinoma.
  • Both groups were homogeneous regarding age, gender and preoperative stage of the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Dec 14;348(9042):1605-10 [8961989.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):92-6 [10773140.001]
  • [Cites] Pathol Oncol Res. 2002;8(1):7-17 [11994757.001]
  • [Cites] Strahlenther Onkol. 2001 Apr;177(4):173-81 [11370551.001]
  • [Cites] Br J Surg. 1993 Oct;80(10):1333-6 [8242317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1076-81 [12419434.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] World J Surg. 1999 May;23(5):463-7; discussion 467-8 [10085394.001]
  • [Cites] Eur J Cancer. 1994;30A(11):1602-6 [7530469.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):1016-7 [9077384.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):1-8 [10766085.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1189-92 [7577019.001]
  • [Cites] Eur J Surg Oncol. 1998 Dec;24(6):528-35 [9870729.001]
  • [Cites] Ann Med. 1997 Apr;29(2):127-33 [9187227.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):495-9 [14517686.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):423-30 [8876883.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1276-83; discussion 1283-4 [10528764.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):167-73 [10211491.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 15947936.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N: Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer; 2007 Oct 1;110(7):1469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
  • BACKGROUND: Further optimization of dendritic cell (DC)-based vaccines is required clinically against advanced stage cancer.
  • Given the broad range of expression levels observed in the recently defined tumor antigen EphA2 in a diverse types of cancers, especially in advanced stage or metastatic cancers, the authors evaluated the effectiveness of vaccination using DCs pulsed with EphA2-derived peptides (Eph-DCs) in a murine colon cancer model.
  • Immunized mice were challenged subcutaneously with EphA2-positive murine colorectal adenocarcinoma (MC38) mouse colon tumors or with EphA2-negative BL6 melanoma tumors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685394.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


91. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol; 2005 May;97(2):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapeutic agents targeting COX-2 and c-erbB-2 are used to treat colon and breast cancers.
  • COX-2 protein expression correlated with histology (P < 0.005) and stage (P < 0.05), but was not associated with patient survival.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Microarray Analysis. Middle Aged


92. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Commane DM, Shortt CT, Silvi S, Cresci A, Hughes RM, Rowland IR: Effects of fermentation products of pro- and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. Nutr Cancer; 2005;51(1):102-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of fermentation products of pro- and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon.
  • Evidence from in vivo and in vitro studies suggests that the consumption of pro- and prebiotics may inhibit colon carcinogenesis; however, the mechanisms involved have, thus far, proved elusive.
  • There are some indications from animal studies that the effects are being exerted during the promotion stage of carcinogenesis.
  • One feature of the promotion stage of colorectal cancer is the disruption of tight junctions, leading to a loss of integrity across the intestinal barrier.
  • We have used the Caco-2 human adenocarcinoma cell line as a model for the intestinal epithelia.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749636.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Oligosaccharides
  •  go-up   go-down


94. Ouellette JR, Harboe-Schmidt JE, Luthringer D, Brackert S, Silberman AW: Colorectal cancer metastasis presenting as a testicular mass: case report and review of the literature. Am Surg; 2007 Jan;73(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case describes a 51-year-old white man who presented with an enlarged right testicle 9 months after undergoing a right hemicolectomy for a stage IIIC colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Testicular Neoplasms / secondary


95. Woznick AR, Braddock AL, Dulai M, Seymour ML, Callahan RE, Welsh RJ, Chmielewski GW, Zelenock GB, Shanley CJ: Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg; 2005 Mar;189(3):297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have documented differential lysyl oxidase expression in the stromal reaction to colon, breast, prostate, and lung cancer.
  • The present study was undertaken to test the hypothesis that lysyl oxidase mRNA and protein expression decrease with advancing tumor stage in patients with bronchogenic carcinoma.
  • RESULTS: Real-time polymerase chain reaction studies documented a 3.4-fold graded decrease in lysyl oxidase mRNA levels as tumors progressed from stage I to IV.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Bronchogenic / enzymology. Lung Neoplasms / enzymology. Protein-Lysine 6-Oxidase / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792754.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.4.3.13 / Protein-Lysine 6-Oxidase
  •  go-up   go-down


96. Kuester D, Dalicho S, Mönkemüller K, Benedix F, Lippert H, Guenther T, Roessner A, Meyer F: Synchronous multifocal colorectal carcinoma in a patient with delayed diagnosis of ulcerative pancolitis. Pathol Res Pract; 2008;204(12):905-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the resection specimen, four clinically unsuspected, partly mucinous adenocarcinomas accompanied by several foci of low- and high-grade dysplasia were found in the left colon and rectum.
  • At the time of colectomy, advanced tumor stage was diagnosed and classified as pT3c(4) pN1(2/120) M0 V1 R0, UICC stage IIIB, G2.
  • [MeSH-major] Adenocarcinoma / pathology. Colitis, Ulcerative / complications. Colitis, Ulcerative / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Zentralbl Chir. 2015 Dec;140(6):624-6 [25076166.001]
  • (PMID = 18842350.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, Wan DS, Pan ZZ, Zhou ZW: Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients. Chin J Cancer; 2010 Aug;29(8):761-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
  • In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer.
  • METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study.
  • Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model.
  • LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers.
  • The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Chromosome 18q-.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I, Sherman Y: Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol; 2006 Jun;19(6):878-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence.
  • Here, we employed anti-heparanase 733 polyclonal antibody that preferentially recognizes the 50 kDa active heparanase subunit over the 65 kDa proenzyme, as well as anti-heparanase 92.4 monoclonal antibody that recognizes both the latent and the active enzyme, to follow heparanase expression, processing and localization throughout the adenoma-carcinoma transition of the colon epithelium.
  • Interestingly, although reactivity with antibody 733 was markedly reduced in severe dysplasia and in colorectal carcinoma, response to antibody 92.4 exhibited the opposite trend and staining intensities increased in parallel with tumor stage, the highest being in carcinoma cells.
  • Involvement of latent heparanase (detected by 92.4, but not by 733 antibody) in tumor progression was suggested by activation of the Akt/PKB signal transduction pathway upon heparanase overexpression or exogenous addition to HT29 human colon carcinoma cells.
  • These results suggest that heparanase expression is induced during colon carcinogenesis, and that its processing, conformation and localization are tightly regulated during the course of colon adenoma-carcinoma progression.
  • [MeSH-major] Adenocarcinoma / enzymology. Colon / enzymology. Colorectal Neoplasms / enzymology. Glucuronidase / metabolism. Intestinal Mucosa / enzymology